Join
Live feed
·
PRReleasevia Quantisnow
Intellia Therapeutics Inc. logo

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

ByQuantisnow·Wall Street's wire, on your screen.
NTLA· Intellia Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NTLA (Intellia Therapeutics Inc.) and more on Quantisnow.